drugset / Trial / NCT00316719
Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is designed to compare the efficacy and safety of adefovir dipivoxil 10 mg with lamivudine 100 mg in Japanese patients with compensated chronic hepatitis B over 52-week periods.
Timeline
- Start
- 2006-01
- Primary completion
- 2008-01
- Completion
- 2008-01
Outcome
Met primary endpoint
registry analysis (non-inferiority or equivalence test); Adefovir (ADV) vs Lamivudine (LAM); p <0.001; Mean Difference (Net) -0.33 (95% CI -0.94 to 0.28); ANCOVA NCT00316719 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adefovir dipivoxil | Small molecule | 10 mg | Oral |
| Comparator | Lamivudine | Other / unclassified | 100 mg | Oral |